Skip to content

Ocular Therapeutix OCUL Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$198.6M+10.6%
Bausch + Lomb logo
Bausch + LombBLCO
$38M+245%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$975K+3,582%
PBH
Prestige Consumer HealthcarePBH
$55K
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$11.73M+257%
LQD
Liquidia CorporationLQDA
$2.78M+441%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's increase (decrease) in prepaid expense and other assets?
Ocular Therapeutix (OCUL) reported increase (decrease) in prepaid expense and other assets of $357K in Q1 2026.
How has Ocular Therapeutix's increase (decrease) in prepaid expense and other assets changed year-over-year?
Ocular Therapeutix's increase (decrease) in prepaid expense and other assets increased by 109.1% year-over-year, from -$3.93M to $357K.
What is the long-term trend for Ocular Therapeutix's increase (decrease) in prepaid expense and other assets?
Over 2 years (2021 to 2024), Ocular Therapeutix's increase (decrease) in prepaid expense and other assets has grown at a 648.8% compound annual growth rate (CAGR), from $101K to $5.66M.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.